The Food and Drug Administration has approved Beyfortus, or nirsevimab-alip, to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants entering their first RSV season and in certain vulnerable children through 24 months of age entering a second season. The July 17 approval introduces a long-acting monoclonal antibody designed to provide protection through roughly five months—the length of a typical RSV season—with a single intramuscular dose.

The decision is important because RSV remains one of the most common causes of serious respiratory illness in infants. Unlike a vaccine, nirsevimab supplies antibodies directly rather than requiring an infant’s immune system to generate them. That distinction allows protection to begin soon after administration and makes the product potentially applicable across a broad infant population rather than only children with a narrow set of high-risk conditions.

Clinical trials showed substantial reductions in medically attended disease

The FDA’s trial summary describes evidence from randomized studies spanning preterm, late-preterm and term infants. In the phase 2b study of 1,453 preterm infants, nirsevimab reduced medically attended RSV lower respiratory tract disease by 70.1% compared with placebo. In the phase 3 MELODY study, the reduction was approximately 75% through 150 days after dosing.

The peer-reviewed MELODY trial, published in the New England Journal of Medicine, randomized 1,490 healthy late-preterm and term infants. Medically attended RSV-associated lower respiratory tract infection occurred in 1.2% of infants receiving nirsevimab and 5.0% receiving placebo, corresponding to 74.5% efficacy in the primary analysis. Serious adverse-event rates were similar between groups.

An earlier preterm-infant trial involving 1,453 participants found a 70.1% reduction in medically attended RSV lower respiratory tract infection. Together, those studies established efficacy across populations that differ in gestational age and baseline vulnerability.

A broad preventive strategy replaces repeated seasonal dosing for many infants

Sanofi said in its approval announcement that Beyfortus is intended as a single administration timed either to the beginning of RSV season or at birth for infants born during the season. The approved first-season dose is 50 milligrams for infants weighing less than 5 kilograms and 100 milligrams for those weighing at least 5 kilograms. Certain children remaining vulnerable during a second RSV season can receive a higher dose.

AstraZeneca, which leads development and manufacturing, described the approval in its own July 17 statement as the first preventive option specifically designed to protect a broad infant population through a first RSV season. The companies say they plan to make the product available in the United States ahead of the 2023–24 season.

The distinction from palivizumab, the older monoclonal antibody used primarily in high-risk infants, is operationally important. Palivizumab generally requires repeated monthly injections during RSV season. Nirsevimab’s engineered extended half-life is intended to make one seasonal administration sufficient for many infants.

FDA advisers examined both efficacy and safety before approval

The agency’s June advisory-committee record includes FDA and AstraZeneca briefing documents, presentations, meeting minutes and a transcript. Advisers unanimously supported a favorable benefit-risk assessment for use in infants entering their first RSV season and also supported use in certain children entering a second season.

Across the development program, the most commonly reported adverse reactions included rash and injection-site reactions. The FDA also warns that serious hypersensitivity reactions can occur and that the product should be used cautiously in children with clinically significant bleeding disorders because it is given intramuscularly.

Safety evidence in more vulnerable infants has also been reported. A New England Journal of Medicine report from a study involving preterm infants and children with congenital heart or chronic lung disease found no new safety concerns compared with palivizumab during the first RSV season.

The next challenge is translating approval into population protection

The FDA action establishes that nirsevimab can be marketed, but the practical public-health effect will depend on recommendations, supply, pricing and how quickly hospitals and pediatric practices integrate the product into routine infant care. Because the antibody is administered directly to infants, decisions about timing will need to account for birth month, local RSV seasonality and whether a child remains at elevated risk entering a second season.

The approval arrives after an unusually difficult 2022–23 respiratory-virus season that strained pediatric hospitals in many parts of the country. A preventive product that can cover an entire RSV season with one dose could reduce outpatient visits, emergency care and hospitalizations if uptake is broad and the trial results translate into routine practice.

Beyfortus therefore represents a shift in RSV prevention from a strategy concentrated on a relatively small group of high-risk infants toward one that can potentially protect most babies during the period when they are most vulnerable. The clinical evidence supports that broader approach; the coming season will begin to show how effectively the health system can deliver it.